Brought to you by 
J&J gets rights to Vertex's VX950 for HCV; Janssen buys royalty rights
02 Jun 2015
Executive Summary
Johnson & Johnson's Tibotec Pharmaceuticals (focused on the development of anti-infective therapeutics) and Janssen Pharmaceutica NV divisions have signed on to develop and market Vertex Pharmaceuticals's VX950, an investigational oral hepatitis C virus (HCV) protease inhibitor. The exclusive agreement covers Europe, South America, the Middle East, Africa, and Australia. Vertex keeps exclusive marketing rights in North America.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J gets rights to Vertex's VX950 for HCV; Janssen buys royalty rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice